Elekta : to become new issuer in the Swedish commercial paper market
June 12, 2024 at 06:35 am
Share
English
Swedish
Published: 2024-06-12 07:30:00 CEST
Elekta AB
Investor News
Elekta to become new issuer in the Swedish commercial paper market
STOCKHOLM - Elekta (EKTA-B.ST) has access to cost-effective and diverse financing. To further expand the range of available funding options, Elekta continuously reviews opportunities to utilize other sources of funding on the credit market. The company will therefore launch a Swedish commercial paper program in June 2024.
The commercial paper market is an established source of short-term financing for maturities of up to 12 months. The program is aimed primarily at increasing financing flexibility in short-term liquidity management. Danske Bank is the arranger and is also an issuing agent, together with SEB.
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on "X", formerly known as Twitter.
Attachments:
Sweden Commercial Paper 2024 EN.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
Elekta AB published this content on
12 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
12 June 2024 05:34:09 UTC.
Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
ELEKTA AB 
